Assessing promoter methylation as an epigenetic regulator that is associated with the differential expression of PLA2R1 in breast cancer may potentially define novel therapeutic targets, diagnostic and/or prognostic biomarkers. Here, PLA2R1 is linked to breast carcinoma.